BIOGEN PUBLISHES 2022 ESG REPORT

May 1, 2023 • Company Statements

Biogen has published its 2022 ESG Report, which supports Biogen’s business goals by sharing our corporate responsibility story, disclosing key environmental, social, and governance (ESG) data and providing updated progress against our targets and commitments. You can find a copy here.

Biogen Safe Harbor
This statement includes forward-looking statements based on our current expectations and beliefs that are subject to risks and uncertainties. Our actual results may differ materially. Please consult the risk factors section of our SEC filings.

September 29, 2023

FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®

TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United States FDA approval is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE to the reference product ACTEMRA CAMBRIDGE, Mass., Sept.

September 26, 2023

Biogen Completes Acquisition of Reata Pharmaceuticals

Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – has completed the acquisition